Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials -- Ignore unavailable to you. Want to Upgrade?

To: Brian Malloy who wrote (135)	11/30/1999 11:55:00 PM
From: Brian Malloy	Respond to of 250

Interesting book review about the possible origin of the virus. New Book Challenges Theories of AIDS Origins nytimes.com

To: Brian Malloy who wrote (135)	12/1/1999 3:00:00 AM
From: glen	Read Replies (1) \| Respond to of 250

Welcome to VaxGen. Your investment objectives are exactly as they should be. The wait should be closer to two years, rather than three, and the FDA can move faster if the results of Phase 3 Trials are favorable. If VaxGen does succeed in obtaining FDA approval, this could be a $200 stock. Their potential target market will be the world's population. This is a company with little hype, and very much under-rated and misunderstood. They have a much better chance of succeeding than most realize. Regards, glen